NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
Clinical Trials
8 trialsNCT04551521 2025-01-08
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
Phase 2 Completed
NCT01636908 2021-04-15
ICK
Amsterdam UMC, location VUmc
Phase NA Completed
NCT01739764 2021-01-07
An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Hoffmann-La Roche
Phase 4 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT01767623 2018-02-13
A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants
Hoffmann-La Roche
Phase 1 Completed
NCT01286753 2016-09-07
A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Hoffmann-La Roche
Phase 2 Completed
NCT01673737 2015-04-10
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
Sanofi
Phase 1 Completed